The ATM regulated DNA damage response pathway as a chemoand radiosensitisation target

Expert Opinion on Drug Discovery

Volumn 4, Issue 5, 2009, Pages 495-505

  Alao, John P ^a  

^a UNIVERSITY OF GOTHENBURG   (Sweden)

Author keywords

ATM; Cancer therapy; Chemosensitisation; DNA damage checkpoint; Radiosensitisation

Indexed keywords

12 (2 CYANOETHYL) 6,7,12,13 TETRAHYDRO 13 METHYL 5 OXOINDOLO[2,3 A]PYRROLO[3,4 C]CARBAZOLE; 2 MORPHOLINO 6 (1 THIANTHRENYL) 4 PYRANONE; 7 HYDROXYSTAUROSPORINE; A 641397; A 690002; ANTINEOPLASTIC AGENT; ATM PROTEIN; CAFFEINE; CARBOPLATIN; CGK 733; CISPLATIN; DOXORUBICIN; EXEL 9844; GEMCITABINE; METHYLXANTHINE; NSC 109555; PENTOXIFYLLINE; PROTEIN P53; SB 218078; UNCLASSIFIED DRUG; VRX 0466617;

CELL CYCLE G1 PHASE; CELL CYCLE G2 PHASE; CELL CYCLE PROGRESSION; CELL CYCLE S PHASE; CELL DEATH; CHEMOSENSITIZATION; CLINICAL TRIAL; DNA DAMAGE; DNA REPAIR; DRUG ACTIVITY; DRUG INHIBITION; DRUG POTENTIATION; DRUG SENSITIVITY; HUMAN; NONHUMAN; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; PROTEIN STRUCTURE; RADIOSENSITIZATION; REVIEW;

EID: 67649090640     PISSN: 17460441     EISSN: None     Source Type: Journal    
DOI: 10.1517/17460440902835475     Document Type: Review

References (153)

1. Zhou BB, Bartek J. Targeting the checkpoint kinases: chemosensitization versus chemoprotection. Nat Rev Cancer 2004;4(3):216-25
2. Blasina A, Price BD, Turenne GA, McGowan CH. Caffeine inhibits the checkpoint kinase ATM. Curr Biol 1999;9(19):1135-8
3. Gaudin D, Yielding KL. Response of a "resistant" plasmacytoma to alkylating agents and x-ray in combination with the "excision" repair inhibitors caffeine and chloroquine. Proc Soc Exp Biol Med 1969;131(4):1413-16
4. Sarkaria JN, Tibbetts RS, Busby EC, et al. Inhibition of phosphoinositide 3-kinase related kinases by the radiosensitizing agent wortmannin. Cancer Res 1998;58(19):4375-82
5. Zhou BB, Chaturvedi P, Spring K, et al. Caffeine abolishes the mammalian G(2)/M DNA damage checkpoint by inhibiting ataxia-telangiectasia-mutated kinase activity. J Biol Chem 2000;275(14):10342-8
6. Kawabe T. G2 checkpoint abrogators as anticancer drugs. Mol Cancer Ther 2004;3(4):513-19
7. Lavin MF. Ataxia-telangiectasia: from a rare disorder to a paradigm for cell signalling and cancer. Nat Rev Mol Cell Biol 2008;9(10):759-69
8. Savitsky K, Bar-Shira A, Gilad S, et al. A single ataxia telangiectasia gene with a product similar to PI-3 kinase. Science 1995;268(5218):1749-53
9. Lee JH, Paull TT. Activation and regulation of ATM kinase activity in response to DNA double-strand breaks. Oncogene 2007;26(56):7741-8
10. Bakkenist CJ, Kastan MB. DNA damage activates ATM through intermolecular autophosphorylation and dimer dissociation. Nature 2003;421(6922):499-506
11. Kozlov SV, Graham ME, Peng C, et al. Involvement of novel autophosphorylation sites in ATM activation. EMBO J 2006;25(15):3504-14
12. Sun Y, Jiang X, Chen S, et al. A role for the Tip60 histone acetyltransferase in the acetylation and activation of ATM. Proc Natl Acad Sci USA 2005;102(37):13182-7
13. Lavin MF, Birrell G, Chen P, et al. ATM signaling and genomic stability in response to DNA damage. Mutat Res 2005;569(1-2):123-32
14. Lavin MF, Shiloh Y. The genetic defect in ataxia-telangiectasia. Annu Rev Immunol 1997;15:177-202
15. Zhang N, Chen P, Khanna KK, et al. Isolation of full-length ATM cDNA and correction of the ataxia-telangiectasia cellular phenotype. Proc Natl Acad Sci USA 1997;94(15):8021-6
16. Ziv Y, Bar-Shira A, Pecker I, et al. Recombinant ATM protein complements the cellular A-T phenotype. Oncogene 1997;15(2):159-67
17. Banin S, Moyal L, Shieh S, et al. Enhanced phosphorylation of p53 by ATM in response to DNA damage. Science 1998;281(5383):1674-7
18. Canman CE, Lim DS, Cimprich KA, et al. Activation of the ATM kinase by ionizing radiation and phosphorylation of p53. Science 1998;281(5383):1677-9
19. Kurz EU, Lees-Miller SP. DNA damage-induced activation of ATM and ATM-dependent signaling pathways. DNA Repair 2004;3(8-9):889-900
20. Bonilla CY, Melo JA, Toczyski DP. Colocalization of sensors is sufficient to activate the DNA damage checkpoint in the absence of damage. Mol Cell 2008;30(3):267-76
21. Soutoglou E, Misteli T. Activation of the cellular DNA damage response in the absence of DNA lesions. Science 2008;320(5882):1507-10
22. Kanu N, Behrens A. ATMINistrating ATM signalling: regulation of ATM by ATMIN. Cell Cycle 2008;7(22):3483-6
23. Berkovich E, Monnat RJ Jr, Kastan MB. Roles of ATM and NBS1 in chromatin structure modulation and DNA double-strand break repair. Nat Cell Biol 2007;9(6):683-90
24. Cann KL, Hicks GG. Regulation of the cellular DNA double-strand break response. Biochem Cell Biol 2007;85(6):663-74
25. Burma S, Chen BP, Murphy M, et al. ATM phosphorylates histone H2AX in response to DNA double-strand breaks. J Biol Chem 2001;276(45):42462-7
26. Anderson L, Henderson C, Adachi Y. Phosphorylation and rapid relocalization of 53BP1 to nuclear foci upon DNA damage. Mol Cell Biol 2001;21(5):1719-29
27. Schultz LB, Chehab NH, Malikzay A, Halazonetis TD. p53 binding protein 1 (53BP1) is an early participant in the cellular response to DNA double-strand breaks. J Cell Biol 2000;151(7):1381-90
28. Bassing CH, Suh H, Ferguson DO, et al. Histone H2AX: a dosage-dependent suppressor of oncogenic translocations and tumors. Cell 2003;114(3):359-70
29. Celeste A, Fernandez-Capetillo O, Kruhlak MJ, et al. Histone H2AX phosphorylation is dispensable for the initial recognition of DNA breaks. Nat Cell Biol 2003;5(7):675-9
30. Lou Z, Minter-Dykhouse K, Franco S, et al. MDC1 maintains genomic stability by participating in the amplification of ATM-dependent DNA damage signals. Mol Cell 2006;21(2):187-200 (Pubitemid 43099935)
31. Lukas C, Melander F, Stucki M, et al. Mdc1 couples DNA double-strand break recognition by Nbs1 with its H2AX-dependent chromatin retention. EMBO J 2004;23(13):2674-2683 (Pubitemid 38988238)
32. Stucki M, Jackson SP. gammaH2AX and MDC1: anchoring the DNA-damage-response machinery to broken chromosomes. DNA Repair 2006;5(5):534-543
33. Huen MS, Grant R, Manke I, et al. RNF8 transduces the DNA-damage signal via histone ubiquitylation and checkpoint protein assembly. Cell 2007;131(5):901-914 (Pubitemid 350138083)
34. Kolas NK, Chapman JR, Nakada S, et al. Orchestration of the DNA-damage response by the RNF8 ubiquitin ligase. Science 2007;318(5856):1637-1640 (Pubitemid 350233664)
35. Mailand N, Bekker-Jensen S, Faustrup H, et al. RNF8 ubiquitylates histones at DNA double-strand breaks and promotes assembly of repair proteins. Cell 2007;131(5):887-900 (Pubitemid 350138084)
36. Goldberg M, Stucki M, Falck J, et al. MDC1 is required for the intra-S-phase DNA damage checkpoint. Nature 2003;421(6926):952-956 (Pubitemid 36288027)
37. Xu B, O'Donnell AH, Kim ST, Kastan MB. Phosphorylation of serine 1387 in Brca1 is specifically required for the Atm-mediated S-phase checkpoint after ionizing irradiation. Cancer Res 2002;62(16):4588-4591 (Pubitemid 34898582)
38. Mirzoeva OK, Petrini JH. DNA damage-dependent nuclear dynamics of the Mre11 complex. Mol Cell Biol 2001;21(1):281-288
39. Cerosaletti K, Wright J, Concannon P. Active role for nibrin in the kinetics of atm activation. Mol Cell Biol 2006;26(5):1691-1699 (Pubitemid 43297401)
40. Lee JH, Paull TT. Direct activation of the ATM protein kinase by the Mre11/Rad50/Nbs1 complex. Science 2004;304(5667):93-96 (Pubitemid 38451463)
41. Lee JH, Paull TT. ATM activation by DNA double-strand breaks through the Mre11-Rad50-Nbs1 complex. Science 2005;308(5721):551-554 (Pubitemid 40570585)
42. Uziel T, Lerenthal Y, Moyal L, et al. Requirement of the MRN complex for ATM activation by DNA damage. EMBO J 2003;22(20):5612-5621 (Pubitemid 37279970)
43. Lim DS, Kim ST, Xu B, et al. ATM phosphorylates p95/nbs1 in an S-phase checkpoint pathway. Nature 2000;404(6778):613-617 (Pubitemid 30205060)
44. Yazdi PT, Wang Y, Zhao S, et al. SMC1 is a downstream effector in the ATM/NBS1 branch of the human S-phase checkpoint. Genes Dev 2002;16(5):571-582 (Pubitemid 34212490)
45. Li L, Zou L. Sensing, signaling, and responding to DNA damage: organization of the checkpoint pathways in mammalian cells. J Cell Biochem 2005;94(2):298-306 (Pubitemid 41420308)
46. Levine AJ. p53, the cellular gatekeeper for growth and division. Cell 1997;88(3):323-331 (Pubitemid 27131374)
47. Siliciano JD, Canman CE, Taya Y, et al. DNA damage induces phosphorylation of the amino terminus of p53. Genes Dev 1997;11(24):3471-3481 (Pubitemid 28023968)
48. Chehab NH, Malikzay A, Appel M, Halazonetis TD. Chk2/hCds1 functions as a DNA damage checkpoint in G(1) by stabilizing p53. Genes Dev 2000;14(3):278-288
49. Chehab NH, Malikzay A, Stavridi ES, Halazonetis TD. Phosphorylation of Ser-20 mediates stabilization of human p53 in response to DNA damage. Proc Natl Acad Sci USA 1999;96(24):13777-13782
50. Matsuoka S, Huang M, Elledge SJ. Linkage of ATM to cell cycle regulation by the Chk2 protein kinase. Science 1998;282(5395):1893-1897 (Pubitemid 28555269)
51. Haupt Y, Maya R, Kazaz A, Oren M. Mdm2 promotes the rapid degradation of p53. Nature 1997;387(6630):296-299 (Pubitemid 27220766)
52. Khosravi R, Maya R, Gottlieb T, et al. Rapid ATM-dependent phosphorylation of MDM2 precedes p53 accumulation in response to DNA damage. Proc Natl Acad Sci USA 1999;96(26):14973-14977 (Pubitemid 30019749)
53. el-Deiry WS, Tokino T, Velculescu VE, et al. WAF1, a potential mediator of p53 tumor suppression. Cell 1993;75(4):817-825
54. Bartek J, Lukas J. Mammalian G1- and S-phase checkpoints in response to DNA damage. Curr Opin Cell Biol 2001;13(6):738-747 (Pubitemid 33042735)
55. Bartek J, Lukas J. Pathways governing G1/S transition and their response to DNA damage. FEBS Lett 2001;490(3):117-122 (Pubitemid 32171930)
56. Sherr CJ, Roberts JM. Inhibitors of mammalian G1 cyclin-dependent kinases. Genes Dev 1995;9(10):1149-1163
57. Chang BD, Swift ME, Shen M, et al. Molecular determinants of terminal growth arrest induced in tumor cells by a chemotherapeutic agent. Proc Natl Acad Sci USA 2002;99(1):389-394 (Pubitemid 34060371)
58. Falck J, Mailand N, Syljuasen RG, et al. The ATM-Chk2-Cdc25A checkpoint pathway guards against radioresistant DNA synthesis. Nature 2001;410(6830):842- 847 (Pubitemid 32303786)
59. Mailand N, Falck J, Lukas C, et al. Rapid destruction of human Cdc25A in response to DNA damage. Science 2000;288(5470):1425-1429 (Pubitemid 30366329)
60. Meulmeester E, Pereg Y, Shiloh Y, Jochemsen AG. ATM-mediated phosphorylations inhibit Mdmx/Mdm2 stabilization by HAUSP in favor of p53 activation. Cell Cycle 2005;4(9):1166-1170 (Pubitemid 41365384)
61. Okamoto K, Kashima K, Pereg Y, et al. DNA damage-induced phosphorylation of MdmX at serine 367 activates p53 by targeting MdmX for Mdm2-dependent degradation. Mol Cell Biol 2005;25(21):9608-9620 (Pubitemid 41507859)
62. Stad R, Ramos YF, Little N, et al. Hdmx stabilizes Mdm2 and p53. J Biol Chem 2000;275(36):28039-28044 (Pubitemid 30688924)
63. Danovi D, Meulmeester E, Pasini D, et al. Amplification of Mdmx (or Mdm4) directly contributes to tumor formation by inhibiting p53 tumor suppressor activity. Mol Cell Biol 2004;24(13):5835-5843 (Pubitemid 38787968)
64. Ramos YF, Stad R, Attema J, et al. Aberrant expression of HDMX proteins in tumor cells correlates with wild-type p53. Cancer Res 2001;61(5):1839-1842 (Pubitemid 32691995)
65. Shvarts A, Steegenga WT, Riteco N, et al. MDMX: a novel p53-binding protein with some functional properties of MDM2. EMBO J 1996;15(19):5349-5357 (Pubitemid 26336217)
66. de Graaf P, Little NA, Ramos YF, et al. Hdmx protein stability is regulated by the ubiquitin ligase activity of Mdm2. J Biol Chem 2003;278(40):38315-38324 (Pubitemid 37221723)
67. Kawai H, Wiederschain D, Kitao H, et al. DNA damage-induced MDMX degradation is mediated by MDM2. J Biol Chem 2003;278(46):45946-45953 (Pubitemid 37432741)
68. Pan Y, Chen J. MDM2 promotes ubiquitination and degradation of MDMX. Mol Cell Biol 2003;23(15):5113-5121 (Pubitemid 36950868)
69. Pereg Y, Shkedy D, de Graaf P, et al. Phosphorylation of Hdmx mediates its Hdm2- and ATM-dependent degradation in response to DNA damage. Proc Natl Acad Sci USA 2005;102(14):5056-5061 (Pubitemid 40503738)
70. Meulmeester E, Maurice MM, Boutell C, et al. Loss of HAUSP-mediated deubiquitination contributes to DNA damage-induced destabilization of Hdmx and Hdm2. Mol Cell 2005;18(5):565-576 (Pubitemid 40726233)
71. Cimprich KA, Cortez D. ATR: an essential regulator of genome integrity. Nat Rev Mol Cell Biol 2008;9(8):616-627 (Pubitemid 352032926)
72. Hurley PJ, Bunz F. ATM and ATR: components of an integrated circuit. Cell Cycle 2007;6(4):414-417 (Pubitemid 46393443)
73. Hurley PJ, Wilsker D, Bunz F. Human cancer cells require ATR for cell cycle progression following exposure to ionizing radiation. Oncogene 2007;26(18):2535-2542 (Pubitemid 46632006)
74. Brown EJ, Baltimore D. ATR disruption leads to chromosomal fragmentation and early embryonic lethality. Genes Dev 2000;14(4):397-402 (Pubitemid 30131885)
75. de Klein A, Muijtjens M, van Os R, et al. Targeted disruption of the cell-cycle checkpoint gene ATR leads to early embryonic lethality in mice. Curr Biol 2000;10(8):479-482 (Pubitemid 30247338)
76. Cuadrado M, Martinez-Pastor B, Fernandez-Capetillo O. "ATR activation in response to ionizing radiation: still ATM territory". Cell Div 2006;1(1):7 (Pubitemid 46731047)
77. Liu Q, Guntuku S, Cui XS, et al. Chk1 is an essential kinase that is regulated by Atr and required for the G(2)/M DNA damage checkpoint. Genes Dev 2000;14(12):1448-1459
78. Lopez-Girona A, Tanaka K, Chen XB, et al. Serine-345 is required for Rad3- dependent phosphorylation and function of checkpoint kinase Chk1 in fission yeast. Proc Natl Acad Sci USA 2001;98(20):11289-11294 (Pubitemid 32928721)
79. Zhao H, Watkins JL, Piwnica-Worms H. Disruption of the checkpoint kinase 1/cell division cycle 25A pathway abrogates ionizing radiation-induced S and G2 checkpoints. Proc Natl Acad Sci USA 2002;99(23):14795-14800 (Pubitemid 35334563)
80. Uto K, Inoue D, Shimuta K, et al. Chk1, but not Chk2, inhibits Cdc25 phosphatases by a novel common mechanism. EMBO J 2004;23(16):3386-3396 (Pubitemid 39209162)
81. Agami R, Bernards R. Distinct initiation and maintenance mechanisms cooperate to induce G1 cell cycle arrest in response to DNA damage. Cell 2000;102(1):55-66
82. Pontano LL, Aggarwal P, Barbash O, et al. Genotoxic stress-induced cyclin D1 phosphorylation and proteolysis are required for genomic stability. Mol Cell Biol 2008;28(23):7245-7258
83. Alao JP. The regulation of cyclin D1 degradation: roles in cancer development and the potential for therapeutic invention. Mol Cancer 2007;6:24 (Pubitemid 46585441)
84. Painter RB, Young BR. Radiosensitivity in ataxia-telangiectasia: a new explanation. Proc Natl Acad Sci USA 1980;77(12):7315-7317 (Pubitemid 11189463)
85. Carney JP, Maser RS, Olivares H, et al. The hMre11/hRad50 protein complex and Nijmegen breakage syndrome: linkage of double-strand break repair to the cellular DNA damage response. Cell 1998;93(3):477-486 (Pubitemid 28232091)
86. Stewart GS, Maser RS, Stankovic T, et al. The DNA double-strand break repair gene hMRE11 is mutated in individuals with an ataxia-telangiectasia-like disorder. Cell 1999;99(6):577-587 (Pubitemid 30004634)
87. Varon R, Vissinga C, Platzer M, et al. Nibrin, a novel DNA double-strand break repair protein, is mutated in Nijmegen breakage syndrome. Cell 1998;93(3):467-476 (Pubitemid 28232090)
88. Jackson JR, Gilmartin A, Imburgia C, et al. An indolocarbazole inhibitor of human checkpoint kinase (Chk1) abrogates cell cycle arrest caused by DNA damage. Cancer Res 2000;60(3):566-572 (Pubitemid 30094552)
89. Pandita TK, Lieberman HB, Lim DS, et al. Ionizing radiation activates the ATM kinase throughout the cell cycle. Oncogene 2000;19(11):1386-1391 (Pubitemid 30171169)
90. Wu X, Ranganathan V, Weisman DS, et al. ATM phosphorylation of Nijmegen breakage syndrome protein is required in a DNA damage response. Nature 2000;405(6785):477-482 (Pubitemid 30367426)
91. Zhao S, Weng YC, Yuan SS, et al. Functional link between ataxiatelangiectasia and Nijmegen breakage syndrome gene products. Nature 2000;405(6785):473-477 (Pubitemid 30367425)
92. Lehmann AR. The role of SMC proteins in the responses to DNA damage. DNA Repair 2005;4(3):309-314 (Pubitemid 40126994)
93. Kim ST, Xu B, Kastan MB. Involvement of the cohesin protein, Smc1, in Atm-dependent and independent responses to DNA damage. Genes Dev 2002;16(5):560-570 (Pubitemid 34212489)
94. Nakanishi K, Taniguchi T, Ranganathan V, et al. Interaction of FANCD2 and NBS1 in the DNA damage response. Nat Cell Biol 2002;4(12):913-920 (Pubitemid 35469420)
95. Bartek J, Lukas C, Lukas J. Checking on DNA damage in S phase. Nat Rev Mol Cell Biol 2004;5(10):792-804 (Pubitemid 39336273)
96. Donzelli M, Draetta GF. Regulating mammalian checkpoints through Cdc25 inactivation. EMBO Rep 2003;4(7):671-677 (Pubitemid 36974751)
97. Sorensen CS, Syljuasen RG, Lukas J, Bartek J. ATR, Claspin and the Rad9-Rad1-Hus1 complex regulate Chk1 and Cdc25A in the absence of DNA damage. Cell Cycle 2004;3(7):941-945 (Pubitemid 40179476)
98. Sorensen CS, Syljuasen RG, Falck J, et al. Chk1 regulates the S phase checkpoint by coupling the physiological turnover and ionizing radiation-induced accelerated proteolysis of Cdc25A. Cancer Cell 2003;3(3):247-258 (Pubitemid 37443880)
99. Busino L, Donzelli M, Chiesa M, et al. Degradation of Cdc25A by beta-TrCP during S phase and in response to DNA damage. Nature 2003;426(6962):87-91 (Pubitemid 37432546)
100. Jin J, Shirogane T, Xu L, et al. SCFbeta-TRCP links Chk1 signaling to degradation of the Cdc25A protein phosphatase. Genes Dev 2003;17(24):3062-3074 (Pubitemid 38040770)
101. Dalal SN, Schweitzer CM, Gan J, DeCaprio JA. Cytoplasmic localization of human cdc25C during interphase requires an intact 14-3-3 binding site. Mol Cell Biol 1999;19(6):4465-4479 (Pubitemid 29242020)
102. Peng CY, Graves PR, Thoma RS, et al. Mitotic and G2 checkpoint control: regulation of 14-3-3 protein binding by phosphorylation of Cdc25C on serine-216. Science 1997;277(5331):1501-1505 (Pubitemid 27449237)
103. Chan TA, Hermeking H, Lengauer C, et al. 14-3-3Sigma is required to prevent mitotic catastrophe after DNA damage. Nature 1999;401(6753):616-620 (Pubitemid 129517080)
104. Reinhardt HC, Aslanian AS, Lees JA, Yaffe MB. p53-deficient cells rely on ATM- and ATR-mediated checkpoint signaling through the p38MAPK/MK2 pathway for survival after DNA damage. Cancer Cell 2007;11(2):175-189 (Pubitemid 46209849)
105. Jackson JR, Zhou BB. G2 checkpoint control: checking in to the last resort for DNA damage. Cancer Biol Ther 2004;3(3):314-316 (Pubitemid 41350886)
106. Alao JP, Sunnerhagen P. Rad3 and Sty1 function in Schizosaccharomyces pombe: an integrated response to DNA damage and environmental stress? Mol Microbiol 2008;68(2):246-254
107. Manke IA, Nguyen A, Lim D, et al. MAPKAP kinase-2 is a cell cycle checkpoint kinase that regulates the G2/M transition and S phase progression in response to UV irradiation. Mol Cell 2005;17(1):37-48 (Pubitemid 40075363)
108. Sidi S, Sanda T, Kennedy RD, et al. Chk1 suppresses a caspase-2 apoptotic response to DNA damage that bypasses p53, Bcl-2, and caspase-3. Cell 2008;133(5):864-877
109. Kuhne M, Riballo E, Rief N, et al. A double-strand break repair defect in ATM-deficient cells contributes to radiosensitivity. Cancer Res 2004;64(2):500-508 (Pubitemid 38120888)
110. Lieber MR. The mechanism of human nonhomologous DNA end joining. J Biol Chem 2008;283(1):1-5
111. Riballo E, Kuhne M, Rief N, et al. A pathway of double-strand break rejoining dependent upon ATM, Artemis, and proteins locating to gamma-H2AX foci. Mol Cell 2004;16(5):715-724
112. Moshous D, Callebaut I, de Chasseval R, et al. Artemis, a novel DNA double-strand break repair/V(D)J recombination protein, is mutated in human severe combined immune deficiency. Cell 2001;105(2):177-186
113. Jeggo PA, Lobrich M. Contribution of DNA repair and cell cycle checkpoint arrest to the maintenance of genomic stability. DNA Repair 2006;5(9-10):1192- 1198 (Pubitemid 44308466)
114. San Filippo J, Sung P, Klein H. Mechanism of eukaryotic homologous recombination. Annu Rev Biochem 2008;77:229-257
115. Sorensen CS, Hansen LT, Dziegielewski J, et al. The cell-cycle checkpoint kinase Chk1 is required for mammalian homologous recombination repair. Nat Cell Biol 2005;7(2):195-201 (Pubitemid 40268135)
116. Zhou BB, Elledge SJ. The DNA damage response: putting checkpoints in perspective. Nature 2000;408(6811):433-439
117. Schuler M, Green DR. Transcription, apoptosis and p53: catch-22. Trends Genet 2005;21(3):182-187
118. Bree RT, Neary C, Samali A, Lowndes NF. The switch from survival responses to apoptosis after chromosomal breaks. DNA Repair 2004;3(8-9):989-995 (Pubitemid 38997941)
119. Chen C, Shimizu S, Tsujimoto Y, Motoyama N. Chk2 regulates transcription-independent p53-mediated apoptosis in response to DNA damage. Biochem Biophys Res Commun 2005;333(2):427-431 (Pubitemid 40848308)
120. Hirao A, Kong YY, Matsuoka S, et al. DNA damage-induced activation of p53 by the checkpoint kinase Chk2. Science 2000;287(5459):1824-1827 (Pubitemid 30143967)
121. Takai H, Naka K, Okada Y, et al. Chk2-deficient mice exhibit radioresistance and defective p53-mediated transcription. EMBO J 2002;21(19):5195-5205
122. Keramaris E, Hirao A, Slack RS, et al. Ataxia telangiectasia-mutated protein can regulate p53 and neuronal death independent of Chk2 in response to DNA damage. J Biol Chem 2003;278(39):37782-37789 (Pubitemid 37175305)
123. Antoni L, Sodha N, Collins I, Garrett MD. CHK2 kinase: cancer susceptibility and cancer therapy - two sides of the same coin? Nat Rev Cancer 2007;7(12):925-936
124. Cresenzi E, Palumbo G, de Boer J, Brady HJ. Ataxia telangiectasia mutated and p21CIP1 modulate cell survival of drug-induced senescent tumor cells: implications for chemotherapy. Clin Cancer Res 2008;14(6):1877-1887
125. Aliouat-Denis CM, Dendouga N, Van den Wyngaert I, et al. p53-independent regulation of p21Waf1/ Cip1 expression and senescence by Chk2. Mol Cancer Res 2005;3(11):627-634 (Pubitemid 41780918)
126. d'Adda di Fagagna F, Reaper Pm, Clay-Farrace L, et al. A DNA damage checkpoint response in telomere-initiated senescence. Nature 2003;426(6963):194-198
127. Sarkaria JN, Eshleman JS. ATM as a target for novel radiosensitizers. Semin Radiat Oncol 2001;11(4):316-327 (Pubitemid 32959666)
128. Taylor AM, Harnden DG, Arlett CF, et al. Ataxia telangiectasia: a human mutation with abnormal radiation sensitivity. Nature 1975;258(5534):427-429
129. Cortez D. Caffeine inhibits checkpoint responses without inhibiting the ataxia-telangiectasia-mutated (ATM) and ATM- and Rad3-related (ATR) protein kinases. J Biol Chem 2003;278(39):37139-37145 (Pubitemid 37175228)
130. Hickson I, Zhao Y, Richardson CJ, et al. Identification and characterization of a novel and specific inhibitor of the ataxia-telangiectasia mutated kinase ATM. Cancer Res 2004;64(24):9152-9159 (Pubitemid 39665530)
131. Hitomi M, Yang K, Stacey AW, Stacey DW. Phosphorylation of cyclin D1 regulated by ATM or ATR controls cell cycle progression. Mol Cell Biol 2008;28(17):5478-5493
132. Matsuoka S, Ballif BA, Smogorzewska A, et al. ATM and ATR substrate analysis reveals extensive protein networks responsive to DNA damage. Science 2007;316(5828):1160-1166 (Pubitemid 46877472)
133. Busby EC, Leistritz DF, Abraham RT, et al. The radiosensitizing agent 7-hydroxystaurosporine (UCN-01) inhibits the DNA damage checkpoint kinase hChk1. Cancer Res 2000;60(8):2108-2112 (Pubitemid 30225168)
134. Graves PR, Yu L, Schwarz JK, et al. The Chk1 protein kinase and the Cdc25C regulatory pathways are targets of the anticancer agent UCN-01. J Biol Chem 2000;275(8):5600-5605 (Pubitemid 30115197)
135. Tsuchida E, Tsuchida M, Urano M. Synergistic cytotoxicity between a protein kinase C inhibitor, UCN-01, and monoclonal antibody to the epidermal growth factor receptor on MDA-468 cells. Cancer Biother Radiopharm 1997;12(2):117-121
136. Wang Q, Fan S, Eastman A, et al. UCN-01: a potent abrogator of G2 checkpoint function in cancer cells with disrupted p53. J Natl Cancer Inst 1996;88(14):956-965 (Pubitemid 26239383)
137. Senderowicz AM. Small-molecule cyclin-dependent kinase modulators. Oncogene 2003;22(42):6609-6620 (Pubitemid 37372341)
138. Welch S, Hirte HW, Carey MS, et al. UCN-01 in combination with topotecan in patients with advanced recurrent ovarian cancer: a study of the Princess Margaret Hospital Phase II consortium. Gynecol Oncol 2007;106(2):305-310 (Pubitemid 47096653)
139. Edelman MJ, Bauer KS Jr, Wu S, et al. Phase I and pharmacokinetic study of 7-hydroxystaurosporine and carboplatin in advanced solid tumors. Clin Cancer Res 2007;13(9):2667-2674 (Pubitemid 46788034)
140. Perez RP, Lewis LD, Beelen AP, et al. Modulation of cell cycle progression in human tumors: a pharmacokinetic and tumor molecular pharmacodynamic study of cisplatin plus the Chk1 inhibitor UCN-01 (NSC 638850). Clin Cancer Res 2006;12(23):7079-7085 (Pubitemid 44974507)
141. Chen Z, Xiao Z, Gu WZ, et al. Selective Chk1 inhibitors differentially sensitize p53-deficient cancer cells to cancer therapeutics. Int J Cancer 2006;119(12):2784-2794 (Pubitemid 44846229)
142. Kohn EA, Yoo CJ, Eastman A. The protein kinase C inhibitor Go6976 is a potent inhibitor of DNA damage-induced S and G2 cell cycle checkpoints. Cancer Res 2003;63(1):31-35 (Pubitemid 36070415)
143. Chen JS, Lin SY, Tso WL, et al. Checkpoint kinase 1-mediated phosphorylation of Cdc25C and bad proteins are involved in antitumor effects of loratadine-induced G2/M phase cell-cycle arrest and apoptosis. Mol Carcinog 2006;45(7):461-478
144. Matthews DJ, Yakes FM, Chen J, et al. Pharmacological abrogation of S-phase checkpoint enhances the anti-tumor activity of gemcitabine in vivo. Cell Cycle 2007;6(1):104-110 (Pubitemid 46173886)
145. Carlessi L, Buscemi G, Larson G, et al. Biochemical and cellular characterization of VRX0466617, a novel and selective inhibitor for the checkpoint kinase Chk2. Mol Cancer Ther 2007;6(3):935-944 (Pubitemid 46554563)
146. Arienti KL, Brunmark A, Axe FU, et al. Checkpoint kinase inhibitors: SAR and radioprotective properties of a series of 2-arylbenzimidazoles. J Med Chem 2005;48(6):1873-1885 (Pubitemid 40396318)
147. D'Amours D, Jackson SP. The Mre11 complex: at the crossroads of dna repair and checkpoint signalling. Nat Rev Mol Cell Biol 2002;3(5):317-327 (Pubitemid 34619266)
148. Xiao Z, Xue J, Sowin TJ, Zhang H. Differential roles of checkpoint kinase 1, checkpoint kinase 2, and mitogen-activated protein kinase-activated protein kinase 2 in mediating DNA damage-induced cell cycle arrest: implications for cancer therapy. Mol Cancer Ther 2006;5(8):1935-1943 (Pubitemid 44336564)
149. Bartek J, Lukas J, Bartkova J. DNA damage response as an anti-cancer barrier: damage threshold and the concept of 'conditional haploinsufficiency'. Cell Cycle 2007;6(19):2344-2347
150. Halazonetis TD, Gorgoulis VG, Bartek J. An oncogene-induced DNA damage model for cancer development. Science 2008;319(5868):1352-1355 (Pubitemid 351354863)
151. Helleday T, Petermann E, Lundin C, et al. DNA repair pathways as targets for cancer therapy. Nat Rev Cancer 2008;8(3):193-204 (Pubitemid 351301852)
152. Xu WS, Parmigiani RB, Marks PA. Histone deacetylase inhibitors: molecular mechanisms of action. Oncogene 2007;26(37):5541-5552 (Pubitemid 47255934)
153. Kumar S, Boehm J, Lee JC. p38 MAP kinases: key signalling molecules as therapeutic targets for inflammatory diseases. Nat Rev Drug Discov 2003;2(9):717-726 (Pubitemid 37361787)